Evidence map›Paper›PMID 32889695›Full record

ArticleInternational journal of hematology2021

Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone.

Ho Sup Lee, Kihyun Kim, Je-Jung Lee, Sung-Soo Yoon, Soo-Mee Bang, Jin Seok Kim, Hyeon-Seok Eom, Dok Hyun Yoon, Yoojin Lee, Ho-Jin Shin and 15 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 20 institutions in 1 country.

Ho Sup LeeDepartment of Internal Medicine, Kosin University College of Medicine, Busan, South Korea.
Kihyun KimDepartment of Medicine, Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, South Korea.
Je-Jung LeeDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo, South Korea.
Sung-Soo YoonDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Soo-Mee BangDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Jin Seok KimDivision of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Hyeon-Seok EomDepartment of Internal Medicine, National Cancer Center of Korea, Goyang, South Korea.
Dok Hyun YoonDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Yoojin LeeDepartment of Hematology/Oncology, Kyungpook National University Hospital, Daegu, South Korea.
Ho-Jin ShinDepartment of Internal Medicine, Pusan National University Hospital, Busan, South Korea.
Yong ParkDepartment of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.
Jae-Cheol JoDepartment of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.
Won Sik LeeDepartment of Internal Medicine, Busan Paik Hospital, Busan, South Korea.
Young Rok DoDepartment of Hemato-Oncology, Keimyung University Dongsan Medical Center, Daegu, South Korea.
Yeung-Chul MunDepartment of Internal Medicine, Ewha Womans University School of Medicine, Seoul, South Korea.
Mark Hong LeeDivision of Hematology-Oncology, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, South Korea.
Hyo Jung KimDepartment of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, South Korea.
Sung-Hyun KimDepartment of Internal Medicine, Dong-A Medical Center, Dong-A University College of Medicine, Busan, South Korea.
Min Kyoung KimDepartment of Medicine, Yeungnam University College of Medicine, Daegu, South Korea.
Sung-Nam LimDepartment of Internal Medicine, Haeundae Baek Hospital, Busan, South Korea.
Seong Kyu ParkDepartment of Hematology/Oncology, Soonchunhyang University Bucheon Hospital, Bucheon, South Korea.
Jun Ho YiDivision of Hematology-Oncology, Department of Medicine, Chung-Ang University, Seoul, South Korea.
Jae Hoon LeeDepartment of Internal Medicine, Gachon University Gil Hospital, Incheon, South Korea.
Chang-Ki MinDepartment of Internal Medicine, Seoul St. Mary's Hospital, Catholic University of Korea, 505, Banpo-dong, Seocho-gu, Seoul, 137-701, South Korea. ckmin@catholic.ac.kr.
Korean Multiple Myeloma Working Party (KMMWP)
University of Ulsan · KRCatholic University of Korea · KRChonnam National University Hwasun Hospital · KRChung-Ang University · KRDeleted InstitutionDong-A University · KREwha Womans University · KRHallym University Sacred Heart Hospital · KRInje University Busan Paik Hospital · KRKeimyung University Dongsan Medical Center · KRKonkuk University Medical Center · KRKorea University · KRKosin University · KRNational Cancer Center · KRPusan National University Hospital · KRSamsung Medical Center · KRSeoul National University Bundang Hospital · KRSeoul National University Hospital · KRSeverance Hospital · KRSoonchunhyang University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We compared efficacy and safety, according to frailty, of elderly patients with relapsed and refractory multiple myeloma (RRMM) treated with lenalidomide and dexamethasone (Rd), for whom bortezomib treatment had failed. Patients, 164 (52.9%) and 146 (47.1%), were classified as non-frail and frail using a simplified frailty scale. The overall response rates (ORR) and survival outcomes were lower in frail than in non-frail patients (ORR: 56.2% vs. 67.7%, P = 0.069; median progression free survival: 13.17 vs. 17.80 months, P = 0.033; median overall survival: 23.00 vs. 36.27 months, P = 0.002, respectively). The number of treatment emergent adverse events in grade 3 or worse was higher in frail than in non-frail patients (41.8% vs. 24.4%, P = 0.002, respectively). In frail patients, independent poor prognostic factors for survival were two or more Charlson comorbidity index (CCI) score, prior to exposure to both bortezomib and thalidomide, and achieved less than partial response In conclusion, frailty could predict clinical outcomes of Rd treatment in elderly patients with RRMM who had failed prior bortezomib. In frail patients, lower CCI in addition to less previous treatment exposure and deep response were associated with better survival.

Indexed as

AgedAged, 80 and overBortezomibDexamethasoneDisease-Free SurvivalDrug Therapy, CombinationFemaleFrailtyHumansLenalidomideMaleMiddle AgedMultiple MyelomaRecurrenceTreatment FailureTreatment OutcomeBortezomibDexamethasoneLenalidomideElderly multiple myelomaFrailtyLenalidomide and dexamethasoneRelapsed and refractorySurvival

Identifiers

PMID32889695
OpenAlexW3083212577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.